IMDELLTRA is a bispecific delta-like ligand 3 (DLL3)-directed CD3 Tcell engager indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.<\/p>\n
IMDELLTRA (tarlatamab-dlle) for injection, for intravenous use Initial U.S. Approval: 2024<\/strong><\/p>\n IMDELLTRA (tarlatamab-dlle) may be accessed in India through a named-patient import process<\/strong>\u00a0with a valid doctor\u2019s prescription, and\u00a0Indian Pharma Network (IPN), New Delhi, assists with compliant sourcing<\/strong>\u00a0and delivery of specialty medicines subject to regulatory approvals.<\/p>\n Indian Pharma Network (IPN), based in New Delhi, helps patients and healthcare providers with the sourcing and import coordination of specialty medicines in compliance with applicable Indian regulations.<\/strong>\u00a0Availability, import eligibility, pricing, and delivery timelines may vary and are subject to regulatory approvals and documentation requirements.<\/p>\n IPN having representation in<\/strong>\u00a0Delhi, Gurugram, Mumbai, Bengaluru, Kolkata, Chennai, Pune, Ahmedabad, Hyderabad, Chandigarh, Jaipur, and Lucknow.<\/p>\n Named-patient import facilitator contact details<\/strong> Patients are advised to independently verify the credentials, licensing, and regulatory compliance of any facilitator before proceeding.<\/em><\/p>\n Note:<\/strong><\/em> NEWS \/ UPDATEs<\/p>\n Note:<\/strong><\/em> <\/p>\n","protected":false},"excerpt":{"rendered":" On May 16, 2024, the Food and Drug Administration granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen, Inc.) for extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.<\/p>\nIs IMDELLTRA (tarlatamab-dlle) available in India?<\/h4>\n
How to get IMDELLTRA injection delivered in India?<\/h4>\n
Who can help source IMDELLTRA injection in India legally?<\/h4>\n
\nCompany Name:<\/strong>\u00a0Indian Pharma Network (IPN)
\nAddress:<\/strong>\u00a060\/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016
\nFor sourcing and import coordination of specialty medicines, contact:<\/strong>
\nMr. Tarun:<\/strong>\u00a0+91 9891 296 838
\nMr. Neeraj:<\/strong>\u00a0+91 9811 747 774
\nEmail:\u00a0info@indianpharmanetwork.co.in<\/a><\/strong><\/p>\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.\u00a0Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India<\/a>. With over two decades of industry experience, IPN offers extensive coverage across India.<\/em><\/p>\n\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.\u00a0Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India<\/a>. With over two decades of industry experience, IPN offers extensive coverage across India.<\/em><\/p>\nBrand Name: IMDELLTRA\u00a0 Generic Name: tarlatamab-dlle \u00a0IMDELLTRA (tarlatamab-dlle) is used to treat adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.<\/h2>\n